Status:

COMPLETED

Assessing the Role of "Statin" Therapy and Perioperative Inflammatory Response in Patients Undergoing Major Orthopedic Surgery

Lead Sponsor:

Mayo Clinic

Conditions:

Perioperative Inflammatory Response

Eligibility:

All Genders

18-80 years

Phase:

PHASE4

Brief Summary

The purpose of the present study is to quantify the degree of modulation, if any, in the perioperative inflammatory response associated with statins use. Specifically, we hypothesize that: In a popul...

Detailed Description

Previous studies have reported activation of the body's immune system during the perioperative period.1 Typically, this "stress response" is limited and goes unnoticed by the patient and health care t...

Eligibility Criteria

Inclusion

  • 1\. Patients scheduled for elective major spine surgery (multilevel (2-6 level) open thoracic or lumbar spine surgery with instrumentation)

Exclusion

  • Pregnancy
  • Lactating females
  • Oral or parenteral corticosteroid use in the past 30 days
  • Elevation of AST or ALT \> 3x normal
  • Elevation of creatinine kinase \> 2x normal
  • Previous adverse drug reaction to any medication in the statin class
  • Current use of fibrates, niacin, itraconazole, ketoconazole, macrolide antibiotics, HIV protease inhibitors and/or nefazodone
  • Active liver disease
  • Current statin use
  • Anti-inflammatory use of the following medications within the last 30 days:
  • Sulfasalazine
  • Mycophenolate
  • Cyclosporine
  • Cyclophosphamide
  • Azathioprine
  • Chlorambucil
  • Minocycline
  • Myochrysine
  • Penicillamine
  • Hydroxychloroquine
  • Leflunomide
  • Any medications listed in 3 or 10 above in the post-operative period
  • Use of Activated protein C at any time during the patients hospitalization
  • Use of anti-inflammatory medications listed below within the last 30 days:
  • Leflunomide
  • Sulfasalazine
  • Mycophenolate
  • Cyclosporine
  • Cyclophosphamide
  • Azathioprine
  • Chlorambucil
  • Minocycline
  • Myochrysine
  • Penicillamine
  • Hydroxychloroquine
  • Methotrexate

Key Trial Info

Start Date :

April 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2016

Estimated Enrollment :

61 Patients enrolled

Trial Details

Trial ID

NCT00656292

Start Date

April 1 2008

End Date

March 1 2016

Last Update

May 19 2017

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Mayo Clinic

Rochester, Minnesota, United States, 55905